Intervention not reported
Chemobased DFS ‐ 5‐FU based chemotherapy DFS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased DFS ‐ 5‐FU based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ Platinum‐based chemotherapy DFS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T1/2 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T3/4 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N‐ OS · patients with resectable gastric cancer
The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Survival · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes survival (very low certainty).
1 finding from 1 review
Intervention not reported
Gastric outlet obstruction Clinical symptoms of vomiting with confirmation of the gastric outlet obstruction by radiological or endoscopic investigations · patients with unresectable periampullary carcinoma
It is very uncertain whether the intervention changes gastric outlet obstruction Clinical symptoms of vomiting with… (very low certainty).
1 finding from 1 review
Intervention not reported
Operating time · patients with unresectable periampullary carcinoma
1 finding from 1 review
Improvements in pain intensity as defined by the trialist (primary outcome) · participants with acute pancreatitis pain
Morphine showed no clear difference in improvements in pain intensity as defined by the trialist (primary… compared with metamizole (low certainty).
1 finding from 1 review
Supplementary analgesic option offered (primary outcome 2) · participants with acute pancreatitis pain
Opioids may leads to lower supplementary analgesic option offered (primary outcome 2) compared with no opioids (low certainty).
1 finding from 1 review
Pancreatitis complications (secondary outcome 1) · participants with acute pancreatitis pain
Opioids showed no clear difference in pancreatitis complications (secondary outcome 1) compared with no opioids (low certainty).
1 finding from 1 review
Adverse drug events · participants with acute pancreatitis pain
Opioids showed no clear difference in any drug‐related adverse event (secondary outcome 2) compared with no opioids (low certainty).
1 finding from 1 review
Nausea and vomiting · participants with acute pancreatitis pain
Opioids showed no clear difference in nausea and vomiting (secondary outcome 2) compared with no opioids (low certainty).
1 finding from 1 review
Sedation and somnolence (secondary outcome 2) · participants with acute pancreatitis pain
Opioids showed no clear difference in sedation and somnolence (secondary outcome 2) compared with no opioids (low certainty).
1 finding from 1 review
Death from any cause (secondary outcome 3) · participants with acute pancreatitis pain
It is very uncertain whether opioids changes death from any cause (secondary outcome 3) compared with no opioids (very low certainty).
1 finding from 1 review
Serious adverse events · people with mild acute gallstone pancreatitis
It is very uncertain whether early changes serious adverse events compared with delayed laparoscopic cholecystectomy (very low certainty).
1 finding from 1 review
Length of hospital stay · people with mild acute gallstone pancreatitis
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA may leads to higher symptomatic remission compared with placebo (low certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review